Risk-adapted chemotherapy of germ cell tumors with carboplatin, etoposide and bleomycin for low-risk and cisplatin, etoposide and ifosfamide for high-risk patients: A single-center study

Oncology

Volumn 59, Issue 2, 2000, Pages 110-117

  Tscherry, G ^a   Jacky, E ^a   Jost, L M ^a   Stahel, R A ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Carboplatin; Chemotherapy; Germ cell tumors; Risk adapted therapy

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CHORIONIC GONADOTROPIN BETA SUBUNIT; CISPLATIN; ETOPOSIDE; IFOSFAMIDE; LACTATE DEHYDROGENASE; MESNA; TUMOR MARKER;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER RISK; CANCER SURVIVAL; DRUG INFUSION; DRUG TOLERABILITY; GERM CELL TUMOR; HUMAN; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; TUMOR VOLUME;

EID: 0033828229     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000012146     Document Type: Article

References (32)

1. Bosl GJ, Motzer RJ: Testicular germ-cell cancer. N Engl J Med 1997;337:242-253.
2. Einhorn LH, Williams SD, Loehrer PJ, Birch R, Drasga R, Omura G, Greco FA: Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: A Southeastern Cancer Study Group Protocol. J Clin Oncol 1989;7:387-391.
3. Saxman SB, Finch D, Gonin R, Einhorn LH: Long-term follow-up of a phase III study of three versus four cycles of bleomycin, etoposide, and cisplatin in favorable-prognosis germ-cell tumors: The Indiana University experience. J Clin Oncol 1989;16:702-706.
4. Bosl GJ, Geller NL, Cirrincione C, Vogelzang NJ, Kennedy BJ, Whitemore WF, Vugrin D, Scher H, Nisselbaum J, Golbey RB: Multivariate analysis of prognostic variables in patients with metastatic testicular cancer. Cancer Res 1983;43:3403-3407.
5. Birch R, Williams S, Cone A, Einhorn L, Roark P, Turner S, Greco FA: Prognostic factors for favorable outcome in disseminated germ cell tumors. J Clin Oncol 1986;4:400-407.
6. Stoter G, Sylvester R, Sleijfer DT, Huinik WW, Kaye SB, Jones WG, van Oosterom AT, Vendrik CPJ, Spaander P, de Pauw M: Multivariate analysis of prognostic factors in patients with disseminated nonseminomatous testicular cancer: Results from a European Organisation for Research on Treatment of Cancer multinstitutional phase III study. Cancer Res 1987; 47:2714-2718.
7. Mead GM, Stenning SP, Parkinson MC, Horwich A, Fossa SD, Wilkinson PM, Kaye SB, Newslands ES, Cook PA: The Second Medical Council Study of prognostic factors in nonseminomatous germ cell tumors. J Clin Oncol 1992;10:85-94.
8. International Germ Cell Classification Consensus Group: International germ cell consensus classification: A prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 1997;15:594-603.
9. Horwich A, Dearnaley DP, Duchesne GM, Williams M, Brada M, Peckham MJ: Simple nontoxic treatment of advanced metastatic seminoma with carboplatin. J Clin Oncol 1989; 7:1150-1156.
10. Horwich A, Dearnaley DP, Nicholls J, Jay G, Mason M, Harland S, Peckham MJ, Hendry WF: Effectiveness of carboplatin, etoposide, and bleomycin combination chemotherapy in good-prognosis metastatic testicular nonseminomatous germ cell tumors. J Clin Oncol 1991; 9:62-69.
11. Bajorin DF, Sarosdy MF, Pfister DG, Mazumdar M, Motzer RJ, Scher HI, Geller NL, Fair WR, Sogani P, Sheinfeld J, Russe P, Vlamis V, Carey R, Vogelzang NJ, Crawford ED, Bosl GJ: Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: A multiinstitutional study. J Clin Oncol 1993;11:598-606.
12. Tjulandin SA, Garin AM, Mescheryakov AA, Perevodchikova NI, Gorbunova VA, Skololov AV, Ljubimova NV, Mironova GT, Molchanov GV, Ozols RF, Hamilton JM: Cisplatin-etoposide and carboplatin-etoposide induction chemotherapy for good risk germ cell tumors. Ann Oncol 1993;4:663-667.
13. Loehrer PJ, Lauer R, Roth BJ, Williams SD, Kalasinski LA, Einhorn LH: Salvage therapy in recurrent germ cell cancer: Ifosfamide and cisplatin plus either vinblastine or etoposide. Ann Intern Med 1988;109:540-546.
14. Motzer RJ, Bajorin DF, Vlamis V, Weisen S, Bosl GJ: Ifosfamide-based chemotherapy for patients with resistant germ cell tumors: The Memorial Sloan-Kettering Cancer Center experience. Semin Oncol 1992;19(suppl 12):8-12.
15. Calvert AH, Newell DR, Gumbrell DR, O'Reilly S, Burnell M, Oxall FE, Siddik ZH, Judson ME, Wiltshaw E: Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989;7: 1748-1756.
16. Bajorin D, Katz A, Chan E, Geller N, Vogelzang N, Bosl GJ: Comparison of criteria for assigning germ cell tumor patients to 'good risk' and 'poor risk' studies. J Clin Oncol 1988;6: 786-792.
17. Horwich A, Sleijfer DT, Fossa SD, Kaye SB, Oliver RTD, Cullen MH, Mead GM, de Wit R, de Mulder PHM, Dearnley DP, Cook PA, Sylvester RJ, Stenning SP: Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic non-seminomatous germ cell cancer: A multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial. J Clin Oncol 1997;15:1844-1852.
18. Levi JA, Raghavan D, Harvey V, Thompson D, Sandeman T, Gill G. Stuart-Harris R, Snyder R, Byrne M, Kerestes Z, Margrie S: The importance of bleomycin in combination chemotherapy for good-prognosis germ cell carcinoma. J Clin Oncol 1993;11:1300-1305.
19. Loehrer PJ, Johnson D, Elson P, Einhorn LH, Trump D: Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: An Eastern Oncology Group Trial. J Clin Oncol 1995;13:470-476.
20. De Wit R, Stoter G, Kaye SB, Sleijfer DT, Jones WG, Huinik WW, Rea LA, Collette L, Sylvester R: Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: A randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. J Clin Oncol 1997;15: 1837-1843.
21. Bokemeyer C, Köhrmann O, Tischler J, Weissbach L, Räth U, Haupt A, Schöffski P, Harstrick A, Schmoll HJ: A randomized trial of cisplatin, etoposide and bleomycin versus carboplatin, etoposide and bleomycin for patients with 'good risk' germ cell tumors. Ann Oncol 1996;7:1015-1022.
22. Childs WJ, Nichols EJ, Horwich A: The optimisation of carboplatin dose in carboplatin, etoposide and bleomycin combination chemotherapy for good prognosis metastatic non-seminomatous germ cell tumours of testis. Ann Oncol 1992;3:291-296.
23. Ratain MJ, Kaminer LS, Bitran JD, Larson RA, Le Beau MM, Skosey C, Purl S, Hoffman PC, Wade J, Vardiman JW: Acute nonlymphocytic leukemia following etoposide and cisplatin combination chemotherapy for advanced non-small-cell carcinoma of the lung. Blood 1987;70:1412-1417.
24. Nichols CR, Breeden ES, Loehrer PJ, Williams SD, Einhorn LH: Secondary leukemia associated with conventional dose of etoposide: Review of serial germ cell tumor protocols. J Natl Cancer Inst 1993;85:36-40.
25. Bajorin DF, Motzer RJ, Rodriguez E, Murphy B, Bosl GJ: Acute nonlymphocytic leukemia in germ cell tumor patients treated with etoposide-containing chemotherapy. J Natl Cancer Inst 1993;85:60-62.
26. Von Leeuwen F, Stiggelbout AM, van den Belt-Dusebout AW, Noyon R, Eliel MR, van Kerkhoff EHM, Delemarre FM, Somers R: Second cancer risk following testicular cancer: A follow-up study of 1,909 patients. J Clin Oncol 1993;11:415-424.
27. Bishoff C, Begent RH, Oliver RT, Rustin GJ, Newlands ES, Andrews R, Skelton M, Holden L, Ong J: Secondary tumors following etoposide containing therapy for germ cell cancer. Ann Oncol 1995;6:35-40.
28. Kollmannsberger C, Beyer J, Droz JP, Harstrick A, Hartmann JT, Biron P, Fléchon A, Schöffski P, Kucyk M, Schmoll HJ, Kanz L, Bokemeyer C: Secondary leukemia following high cumulative dosis of etoposide in patients treated for advanced germ cell tumors. J Clin Oncol 1998;16:3386-3391.
29. Nichols CR, Catalano PJ, Crawford ED, Vogelzang NJ, Einhorn LH, Loehrer PJ: Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: An Eastern Cooperative Oncology Group, Southwest Oncolgy Group, and Cancer and Leukemia Group B Study. J Clin Oncol 1998;16: 1287-1293.
30. Kaye SB, Mead GM, Fossa S, Cullen M, de Wit R, Bodrogi I, van Groeningen C, Sylvester R, Colette L, Stenning S, Prijck L, Lallemand E, de Mulder P: Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: A Randomized Medical Research Council/European Organization for Research and Treatment of Cancer study. J Clin Oncol 1998; 16:692-701.
31. Harding MJ, Paul J, Gillis CR, Kaye SB: Management of malignant teratoma: Does referral to a specialist unit matter? Lancet 1993;341: 999-1002.
32. Collette L, Sylvester RJ, Stenning SP, Fossa SD, Mead GM, de Wit R, de Mulder PHM, Neymark N, Lallemand E, Kaye SB: Impact of treating institutions on survival of patients with poor prognosis metastatic nonseminoma. J Natl Cancer Inst 1999;91:839-846.